
Karuna Therapeutics KRTX
Quartalsbericht 2023-Q3
hinzugefügt 16.05.2026
Karuna Therapeutics Betriebsaufwand 2011-2026 | KRTX
Betriebsaufwand Jährlich Karuna Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 495 M | 300 M | 181 M | 71.8 M | 45.4 M | 14.5 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 495 M | 14.5 M | 185 M |
Betriebsaufwand Vierteljährlich Karuna Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 136 M | 120 M | 110 M | - | 81.1 M | 70.3 M | 58.6 M | - | 51.2 M | 34.5 M | 30 M | - | 19.5 M | 17.8 M | 10.1 M | - | 9.9 M | 15.1 M | 11.6 M | - | 2.47 M | 2.43 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 136 M | 2.43 M | 45.9 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
6.79 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
Esperion Therapeutics
ESPR
|
343 M | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
43.6 M | $ 32.87 | -6.09 % | $ 884 M | ||
|
Forte Biosciences
FBRX
|
70.7 M | $ 21.75 | -1.14 % | $ 282 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | ||
|
Celyad Oncology SA
CYAD
|
26.2 M | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | ||
|
IMV
IMV
|
35.1 M | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
BioNTech SE
BNTX
|
512 M | $ 92.89 | 2.16 % | $ 22.5 B | ||
|
Grifols, S.A.
GRFS
|
1.64 B | $ 8.01 | -1.29 % | $ 5.44 B | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.75 | 5.76 % | $ 466 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Heron Therapeutics
HRTX
|
281 M | $ 0.87 | -0.23 % | $ 145 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
9.17 M | - | -4.36 % | $ 27 M | ||
|
Compugen Ltd.
CGEN
|
32.2 M | $ 2.84 | 8.81 % | $ 265 M | ||
|
Anika Therapeutics
ANIK
|
51.6 M | $ 14.85 | -1.13 % | $ 213 M | ||
|
Advaxis
ADXS
|
19.6 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
10.4 M | $ 3.39 | -1.47 % | $ 5.58 M | ||
|
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Coherus BioSciences
CHRS
|
231 M | $ 1.62 | 2.87 % | $ 190 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
305 M | $ 20.74 | -1.29 % | $ 2.64 B | ||
|
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M |